TCM
CHRS icon

Tang Capital Management’s Coherus Oncology CHRS Stock Holding History

Tang Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,886,748
Closed -$3.19M – 46
2026
Q1 		$3.19M Sell
1,886,748
-837,761
-31% -$1.49M 0.16% 43
2025
Q4 		$3.87M Sell
2,724,509
-2,372,853
-47% -$3.46M 0.19% 61
2025
Q3 		$8.36M Hold
5,097,362
– – 0.32% 70
2025
Q2 		$3.73M Hold
5,097,362
– – 0.19% 96
2025
Q1 		$4.11M Buy
5,097,362
+1,447,362
+40% +$1.67M 0.23% 80
2024
Q4 		$5.04M Buy
3,650,000
+1,300,000
+55% +$1.46M 0.33% 71
2024
Q3 		$2.44M Buy
2,350,000
+1,300,000
+124% +$1.78M 0.17% 93
2024
Q2 		$1.82M Buy
+1,050,000
New +$2.11M 0.19% 80
2023
Q4 		– Sell
-400,000
Closed -$1.5M – 125
2023
Q3 		$1.5M Hold
400,000
– – 0.21% 83
2023
Q2 		$1.71M Buy
400,000
+200,000
+100% +$1.18M 0.25% 74
2023
Q1 		$1.37M Buy
200,000
+84,100
+73% +$653K 0.2% 75
2022
Q4 		$918K Sell
115,900
-634,100
-85% -$4.88M 0.13% 69
2022
Q3 		$7.21M Hold
750,000
– – 0.88% 34
2022
Q2 		$5.43M Hold
750,000
– – 0.82% 31
2022
Q1 		$9.68M Buy
750,000
+100,000
+15% +$1.27M 1.94% 13
2021
Q4 		$10.4M Hold
650,000
– – 2.09% 13
2021
Q3 		$10.4M Hold
650,000
– – 2.17% 11
2021
Q2 		$8.99M Hold
650,000
– – 1.79% 8
2021
Q1 		$9.5M Hold
650,000
– – 2.67% 7
2020
Q4 		$11.3M Buy
650,000
+100,000
+18% +$1.78M 1.72% 6
2020
Q3 		$10.1M Hold
550,000
– – 1.83% 12
2020
Q2 		$9.82M Buy
550,000
+200,000
+57% +$3.39M 0.96% 14
2020
Q1 		$5.68M Buy
+350,000
New +$6.47M 0.8% 14

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Tang Capital Management's CHRS Position: Q2 2026 in Review

Tang Capital Management sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 1,886,748 shares — an estimated $3.19M sold.

Tang Capital Management first reported a position in CHRS in Q1 2020 and held it in 23 quarters. The position peaked at $11.3M in Q4 2020. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Tang Capital Management reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Tang Capital Management sold 1,886,748 Coherus Oncology shares in Q2 2026, an estimated $3.19M.
  • Tang Capital Management first reported a position in Coherus Oncology in Q1 2020 and held it in 23 quarters.
  • Tang Capital Management's Coherus Oncology position peaked at $11.3M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.